Review PODD Momentum Leader Stock Deep Dive result Watch
NMS Β· Healthcare Β· Medical Devices
$136.24
-1.57 (-1.14%)
PODD Interactive Price Chart & Trading Signals
PODD Stock Snapshot β Valuation, Risk & Technical Signals
PODD Key Fundamentals, Analyst Targets & Company Profile
Key Financial Ratios
Market Cap
$9.45B
P/E Ratio
25.56
Forward P/E
17.67
PEG Ratio
1.04
P/B Ratio
6.64
EPS
$5.33
Dividend Yield
β
52W Range
$126.40 β $354.88
Beta
1.08
Volume
0.1M
ROE
26.0%
Profit Margin
12.3%
Revenue Growth
23.5%
Gross Margin
71.1%
EV/EBITDA
16.21
Analyst Target
$171.91
The trailing price-to-earnings ratio stands at 25.6x. Forward P/E of 17.7x implies earnings expansion expected. Price-to-book is 6.64x. EV/EBITDA sits at 16.21x. Market capitalization is $9.45B. Revenue is growing at 23.5% on a trailing basis. Earnings are expanding at 328.6%. Profit margins are 12.3%. Return on equity is 26.0%. Beta of 1.08 indicates market-average volatility.
Analyst Consensus
Recommendation
Buy
Low Target
$144.00
Mean Target
$171.91
High Target
$275.00
Based on 22 analysts
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Deep Dive Analysis
Bottom Line
Verdict
OvervaluedBest for
Growth-oriented investorsWatch out for
Premium valuationData confidence
HighInsulet Corporation (PODD) trades above our multi-model fair value estimate of $73.18 by approximately 46.3%. Trailing P/E: 25.6x. Profitability signals include profit margin of 12.3% and return on equity of 26.0%. Recent growth metrics show revenue growth of 23.5% and earnings growth of 328.6%. Risk profile: beta of 1.08. Consensus: buy.
PODD Deep Dive Analysis
Valuation
Overvalued
P/E 25.6x
Price is above what fundamentals suggest.
Growth
Expanding
Rev 23.5%
Revenue is outpacing the market.
Valuation Snapshot
Insulet Corporation (PODD) trades above our multi-model fair value estimate of $73.18 by approximately 46.3%. The trailing price-to-earnings ratio stands at 25.6x. Forward P/E of 17.7x suggests earnings compression ahead. Price-to-sales is 3.1x. Price-to-book is 6.6x. EV/EBITDA sits at 16.2x. Market capitalization is $9.45B.
Why it matters: Paying a premium works only if the company keeps growing faster than expected.
Growth & Profitability
Revenue is growing at 23.5% on a trailing basis. Earnings are expanding at 328.6%. Profit margins are 12.3%. Return on equity is 26.0%. Return on assets is 9.7%.
Why it matters: Growing revenue with healthy margins usually means the business is gaining market share or pricing power.
Risk Profile
Beta of 1.08 indicates market-average volatility. Net debt position is $413.50M.
Why it matters: Lower risk means steadier returns, but often with less upside in bull markets.
Analyst Context
Analyst consensus target of $171.91 implies 26.2% upside. Target range spans $144.00 to $275.00. 22 analysts cover the stock. Consensus recommendation: buy.
Why it matters: Analyst targets reflect what professionals expect over 12 months. A wide gap between price and target can mean the market disagrees with the consensus.
Investor Fit
Premium valuation is supported by above-average growth, potentially fitting growth-oriented strategies.
Takeaway: Match the stock's risk-reward profile with your own goals and time horizon. No single metric tells the whole story.
Data Methodology & Sources
Market Data (Facts)
- Price, volume, market cap: Yahoo Finance (delayed ~5 min)
- P/E, EPS, revenue, debt: Yahoo Finance fundamentals
- Analyst targets: Yahoo Finance consensus (may lag)
- Insider trades: SEC EDGAR Form 4 filings
QuantSoar Model (Derived)
- Fair Value: 7-model consensus (DCF, Graham, P/E, P/S, DDM, EV/EBITDA, Div Yield) β trimmed inverse-variance weighted
- Margin of Safety = (Fair Value β Live Price) / Live Price Γ 100
- Composite Score: 40% Value + 30% Momentum + 30% Risk
- Verdict Gauge: Base 50 + Valuation(Β±25) + Whale(Β±10) + Macro(Β±10) + Technical(Β±10). Analyst consensus shown separately.
Model outputs are estimates based on available data and are not investment advice. Cross-check with primary sources before making investment decisions.
PODD Overvalued
Insulet Corporation (PODD) trades above our multi-model fair value estimate of $73.18 by approximately 46.3%.
Frequently Asked Questions
ValuationIs PODD stock overvalued right now?
ValuationWhat is PODD fair value based on current fundamentals?
RiskHow risky is PODD compared with other stocks?
GrowthIs PODD still growing?
AnalystWhat do analysts think about PODD?
CatalystWhat could change the investment case for PODD?
Related Stocks
About the Author
Phasakorn Traklang (Peach) β Founder
Phasakorn Traklang (Peach) is the founder of QuantSoar, bringing expertise in SEO, web development, and technical analytics to build an AI-powered investment platform accessible to retail investors worldwide.
Connect on LinkedInInvestment Disclaimer: QuantSoar is for informational purposes only. We do not provide personalized investment advice. Always conduct your own research or consult a financial advisor. SEC
Data: Yahoo Finance / SEC EDGAR / Alpha Vantage / Finnhub. AI outputs verified against source data.